Evidence map›Paper›PMID 35790537›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2022

Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography.

Yu Long, Xiaoying Lv, Xiangming Song, Fuqiang Shao, Hao Ji, Yirui Zhang, Pengxin Qiao, Qingyao Liu, Xiaotian Xia, Ping Lei and 2 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Yu LongDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Ave 1277, Wuhan, 430022, Hubei Province, China.
Xiaoying LvDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Ave 1277, Wuhan, 430022, Hubei Province, China.
Xiangming SongDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Ave 1277, Wuhan, 430022, Hubei Province, China.
Fuqiang ShaoDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Ave 1277, Wuhan, 430022, Hubei Province, China.
Hao JiDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Ave 1277, Wuhan, 430022, Hubei Province, China.
Yirui ZhangDepartment of Immunology, Basic Medical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Pengxin QiaoDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Ave 1277, Wuhan, 430022, Hubei Province, China.
Qingyao LiuDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Ave 1277, Wuhan, 430022, Hubei Province, China.
Xiaotian XiaDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Ave 1277, Wuhan, 430022, Hubei Province, China.
Ping LeiDepartment of Immunology, Basic Medical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yongkang GaiDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Ave 1277, Wuhan, 430022, Hubei Province, China. gykmail@hust.edu.cn.ORCID 0000-0001-6766-5240
Xiaoli LanDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Ave 1277, Wuhan, 430022, Hubei Province, China. LXL730724@hotmail.com.
Ministry of Education · CLHuazhong University of Science and Technology · CNKey Laboratory of Guangdong Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeγδ T cell-based immunotherapy has been rolled out as a promising treatment strategy for malignant tumors due to their potent anti-tumor cytotoxicity, ease of expansion, and unrestricted MHC feature. However, the dynamics and outcomes of γδ T cells in tumor sites are poorly understood. Reported strategies rely on ex vivo biolabeling, significantly limiting the application of γδ T cell molecular imaging. Herein, we investigated whether VLA-4 (very late antigen-4), a crucial component in the effective trafficking of lymphocytes, could serve as a biomarker to non-invasively visualize γδ T cells.

methodsVLA-4-targeted tracer,

results

conclusionTo the best of our knowledge, we reported the first molecular probe,

Indexed as

Integrin alpha4beta1Melanoma, ExperimentalAnimalsCell Line, TumorMiceMolecular ProbesPositron-Emission TomographyPositron Emission Tomography Computed TomographyTissue DistributionT-LymphocytesIntegrin alpha4beta1Molecular ProbesImmunotherapeutic monitoringPositron emission tomography (PET) imagingTumor-infiltrating lymphocytesVery late antigen-4 (VLA-4)γδ T cells

Identifiers

PMID35790537
OpenAlexW4283827598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.